Press release
Brain-Derived Neurotrophic Factor (BDNF) Antagonist Therapeutics-Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments | Array BioPharma Inc., NMS Group - Nerviano Medical Sciences, Takeda, GW Pha
Brain-derived neurotrophic factor (BDNF) is a type of nerve growth factor that stimulates the survival of dorsal root ganglions. The BDNF gene comprises of five exons, including four exons with distinct promoter and fifth exon transcript with the mature BDNF protein.Download the sample report at: https://www.pharmaproff.com/request-sample/1175
The BDNF gene regulation is promoted by several environmental factors such as light stimulation, osmotic stimulation, and whisker stimulation. The light-based stimulation increases BDNF mRNA in the visual cortex area. The BDNF gene regulation is essential for the development of the brain. BDNF is also found to stimulate the neurogenesis, as it increases the number of neurons in striatum, septum, thalamus, and olfactory bulb.
Get the detailed analysis at: https://www.pharmaproff.com/report/bdnf-antagonist-therapeutics
The BDNF is indispensable for learning and memory as in monkey models, it has been observed that the upregulation of BDNF increases learning capability. In addition, BDNF also plays a significant role as neuromodulator in pain transduction. Experimentally, it has been observed that inhibition of BDNF signal transduction inhibits the pain sensitization.
Make enquiry before purchase at: https://www.pharmaproff.com/enquiry/1175
Array BioPharma Inc. is in the process of developing LOXO-195 as a tropomyosin-related kinase antagonist for the treatment of cancer. NMS Group SpA is also developing entrectinib as a tropomyosin receptor kinase B receptor antagonist for the treatment of colorectal cancer and non-small lung cancer. Some of the other companies having pipeline of BDNF antagonist include Takeda Pharmaceutical Company Limited, and GW Pharmaceuticals Plc.
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials. Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.
About Us:
Pharma Proff, is a frontline market intelligence and consulting solutions provider catering to the information and data needs of burgeoning sectors across the world, including pharmaceutical and healthcare. With meticulously curated research reports on the industry landscape, we empower companies in the healthcare and pharmaceutical sectors to make informed business decisions and base their marketing strategies with astuteness.
Contact:
Pharma Proff
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@pharmaproff.com
Web: https://www.pharmaproff.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Brain-Derived Neurotrophic Factor (BDNF) Antagonist Therapeutics-Pipeline Analysis 2018, Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments | Array BioPharma Inc., NMS Group - Nerviano Medical Sciences, Takeda, GW Pha here
News-ID: 1717830 • Views: …
More Releases for BDNF
The Blood Brain Barrier Technologies market to grow vertically in the next decad …
Brain is one of the largest and most complex organs in the human body. It comprises 100 billion nerves that communicate with a 100 trillion synapses. It is made up of hindbrain, midbrain, and forebrain. It is responsible for thought and movement produced by the body. The brain has its own security system-a filtering mechanism comprising blood vessels that allow entry of essential nutrients while blocking other substances-known as the…
Tumor Necrosis Factor Receptor Superfamily Member 16 Market - Overall Industry A …
Tumor Necrosis Factor Receptor Superfamily Member 16
Click here for sample report @ http://www.wiseguyreports.com/sample-request/1473974-tumor-necrosis-factor-receptor-superfamily-member-16-low-affinity-neurotrophin-receptor
Summary
According to the recently published report 'Tumor Necrosis Factor Receptor Superfamily Member 16 - Pipeline Review, H1 2017'; Tumor Necrosis Factor Receptor Superfamily Member 16 (Low Affinity Neurotrophin Receptor p75NTR or Low Affinity Nerve Growth Factor Receptor or Gp80 LNGFR or p75 ICD or TNFRSF16 or CD271 or NGFR) pipeline Target constitutes close to 5 molecules. Out of…
BDNF/NT 3 Growth Factors Receptor - Pipeline Review, H2 2017: Pharmaceuticals In …
“BDNF/NT 3 Growth Factors Receptor” (GP145 TrkB or Neurotrophic Tyrosine Kinase Receptor Type 2 or TrkB Tyrosine Kinase or Tropomyosin Related Kinase B or NTRK2 or EC 2.7.10.1) pipeline Target constitutes close to 19 molecules. Out of which approximately 15 molecules are developed by companies and remaining by the universities/institutes. The latest report BDNFNT 3 Growth Factors Receptor - Pipeline Review, H2 2017, outlays comprehensive information on the BDNF/NT 3…
Current article on Brain Derived Neurotrophic Factor (Abrineurin Or BDNF) - Pipe …
Summary
Global Markets Directs, Brain Derived Neurotrophic Factor (Abrineurin or BDNF) - Pipeline Review, H2 2016, provides in depth analysis on Brain Derived Neurotrophic Factor (Abrineurin or BDNF) targeted pipeline therapeutics.
The report provides comprehensive information on the Brain Derived Neurotrophic Factor (Abrineurin or BDNF), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive…
Current article on Brain Derived Neurotrophic Factor (Abrineurin Or BDNF) - Pipe …
Summary
Global Markets Directs, Brain Derived Neurotrophic Factor (Abrineurin or BDNF) - Pipeline Review, H2 2016, provides in depth analysis on Brain Derived Neurotrophic Factor (Abrineurin or BDNF) targeted pipeline therapeutics.
The report provides comprehensive information on the Brain Derived Neurotrophic Factor (Abrineurin or BDNF), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive…
Explore the Brain Derived Neurotrophic Factor (Abrineurin or BDNF) - Pipeline Re …
Global Markets Directs, Brain Derived Neurotrophic Factor (Abrineurin or BDNF) - Pipeline Review, H2 2016, provides in depth analysis on Brain Derived Neurotrophic Factor (Abrineurin or BDNF) targeted pipeline therapeutics.
The report provides comprehensive information on the Brain Derived Neurotrophic Factor (Abrineurin or BDNF), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive…